Salim Shah
Sarfez Pharmaceuticals, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Salim Shah as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:36 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07046975 · Bioavailability and Bioequivalence Study of Extended Release Torsemide and SpironolactoneSarfez Pharmaceuticals, Inc. · completed · Bioavailability Heathy Volunteers · study director
- Ph3NCT07043634 · A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult SubjectsSarfez Pharmaceuticals, Inc. · completed · Bioavailability Heathy Volunteers · study chair
- Ph3NCT07015671 · Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy SubjectsSarfez Pharmaceuticals, Inc. · completed · Bioequivalence Study in Healthy Subjects, PK/PD · study chair
- Ph4NCT06995144 · Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart FailureSarfez Pharmaceuticals, Inc. · withdrawn · Heart Failure, Edema, Pulmonary Congestion · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:36 UTC. The ranking covers the 200 most relevant of 830 PubMed records, and a shared surname and initials can bring in a namesake. All 830 on PubMed
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.N Engl J Med · 20222,399 citationsRCR 206.5
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.N Engl J Med · 20182,317 citationsRCR 92.6
- Spironolactone for heart failure with preserved ejection fraction.N Engl J Med · 20142,251 citationsRCR 74.8
- Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.N Engl J Med · 20191,979 citationsRCR 92.5
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.N Engl J Med · 20231,432 citationsRCR 160.1
- 1,422 citationsRCR 77.3
- 998 citationsRCR 42.0
- Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.Circulation · 2015882 citationsRCR 29.5
- 781 citationsRCR 126.2
- 738 citationsRCR 24.2